Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$2.97	$3.27	$2.07 ▼ $4.20	$95.67M	0.43	93,621 shs	54,776 shs
CARA Cara Therapeutics		$15.19	$8.13 ▼ $19.08	$24.33M	0.41	22,224 shs	237,144 shs
MGNX MacroGenics	$1.58 -2.5%	$1.51	$0.99 ▼ $5.10	$99.68M	1.65	620,682 shs	530,575 shs
ZURA Zura Bio	$1.66 -3.5%	$1.37	$0.97 ▼ $5.07	$113.50M	-0.06	531,321 shs	470,899 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	0.00%	-0.34%	-11.34%	+12.08%	-4.19%
CARA Cara Therapeutics	0.00%	0.00%	0.00%	0.00%	+34.92%
MGNX MacroGenics	0.00%	+2.60%	+2.60%	0.00%	-52.69%
ZURA Zura Bio	0.00%	+16.90%	-15.31%	+49.55%	-48.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIX Anixa Biosciences	2.5857 of 5 stars	3.5	3.0	0.0	0.0	1.4	3.3	0.0
CARA Cara Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	4.3241 of 5 stars	3.3	3.0	0.0	4.4	2.9	2.5	0.6
ZURA Zura Bio	3.6675 of 5 stars	3.6	5.0	0.0	0.0	3.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIX Anixa Biosciences	3.00	Buy	$9.00	203.03% Upside
CARA Cara Therapeutics	0.00	N/A	N/A	N/A
MGNX MacroGenics	2.57	Moderate Buy	$3.60	127.85% Upside
ZURA Zura Bio	3.13	Buy	$14.17	753.41% Upside

Current Analyst Ratings Breakdown

Latest CARA, MGNX, ZURA, and ANIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	MGNX MacroGenics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $5.00
8/15/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $16.00
8/15/2025	ZURA Zura Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/5/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/10/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/29/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/20/2025	MGNX MacroGenics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	$0.59 per share	N/A
CARA Cara Therapeutics	$7.14M	0.00	N/A	N/A	$12.58 per share	0.00
MGNX MacroGenics	$149.96M	0.66	N/A	N/A	$1.85 per share	0.85
ZURA Zura Bio	N/A	N/A	N/A	N/A	$2.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIX Anixa Biosciences	-$12.55M	-$0.38	N/A	∞	N/A	N/A	-68.17%	-60.38%	9/5/2025 (Estimated)
CARA Cara Therapeutics	-$118.51M	-$21.01	N/A	N/A	N/A	-1,099.76%	-367.97%	-107.43%	N/A
MGNX MacroGenics	-$66.97M	-$0.89	N/A	N/A	N/A	-21.99%	-34.64%	-14.55%	8/19/2025 (Estimated)
ZURA Zura Bio	-$45.39M	-$0.70	N/A	N/A	N/A	N/A	-47.44%	-38.81%	N/A

Latest CARA, MGNX, ZURA, and ANIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/5/2025	Q3 2025	ANIX Anixa Biosciences	-$0.10	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	MGNX MacroGenics	-$0.59	-$0.57	+$0.02	-$0.57	$28.06 million	$22.24 million
8/14/2025	Q2 2025	ZURA Zura Bio	-$0.19	-$0.17	+$0.02	-$0.17	N/A	N/A
6/3/2025	Q2 2025	ANIX Anixa Biosciences	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
CARA Cara Therapeutics	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIX Anixa Biosciences	N/A	8.89	8.89
CARA Cara Therapeutics	N/A	4.77	4.71
MGNX MacroGenics	N/A	3.28	3.11
ZURA Zura Bio	N/A	8.14	8.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIX Anixa Biosciences	29.13%
CARA Cara Therapeutics	44.66%
MGNX MacroGenics	96.89%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
ANIX Anixa Biosciences	25.30%
CARA Cara Therapeutics	3.10%
MGNX MacroGenics	13.00%
ZURA Zura Bio	14.23%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIX Anixa Biosciences	5	32.21 million	24.06 million	Optionable
CARA Cara Therapeutics	80	4.57 million	4.43 million	Optionable
MGNX MacroGenics	430	63.09 million	54.89 million	Optionable
ZURA Zura Bio	3	68.38 million	58.65 million	Optionable

CARA, MGNX, ZURA, and ANIX Headlines

Recent News About These Companies

Zura Bio (NASDAQ:ZURA) Price Target Cut to $16.00 by Analysts at Oppenheimer

August 17 at 10:47 AM | marketbeat.com

Zura Bio (NASDAQ:ZURA) Earns Buy Rating from Chardan Capital

August 17 at 8:29 AM | marketbeat.com

Zura Bio's (ZURA) Buy Rating Reiterated at Chardan Capital

August 17 at 2:59 AM | americanbankingnews.com

Zura Bio (NASDAQ:ZURA) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

August 16 at 12:29 PM | marketbeat.com

Zura Bio price target lowered to $16 from $17 at Oppenheimer

August 15 at 8:33 PM | msn.com

Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

August 14 at 8:15 AM | businesswire.com

Zura Bio (ZURA) to Release Quarterly Earnings on Tuesday

August 11, 2025 | americanbankingnews.com

Zura Bio Limited (NASDAQ:ZURA) Receives Average Recommendation of "Buy" from Brokerages

August 7, 2025 | marketbeat.com

Zura Bio (ZURA) Projected to Post Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Shares Up 7.5% - What's Next?

August 6, 2025 | marketbeat.com

Robert Lisicki on Living Up to Zura Bio’s Heroic Namesake

July 31, 2025 | pharmexec.comP

3 Penny Stocks With Market Caps Over $70M Worth Watching

July 18, 2025 | finance.yahoo.com

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025 | finance.yahoo.com

Zura Bio Announces Chief Financial Officer Transition

July 1, 2025 | businesswire.com

Zura Bio shareholders approve board nominees and auditor

May 24, 2025 | investing.com

Zura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativa

May 21, 2025 | msn.com

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

May 20, 2025 | businesswire.com

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 9, 2025 | standard-journal.comS

After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain

April 24, 2025 | finance.yahoo.com

Zura Bio price target lowered to $3 from $5 at H.C. Wainwright

April 4, 2025 | markets.businessinsider.com

Zura Bio (ZURA) Gets a Buy from Guggenheim

March 31, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARA, MGNX, ZURA, and ANIX Company Descriptions

Anixa Biosciences NASDAQ:ANIX

$2.97 0.00 (0.00%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$3.03 +0.06 (+2.02%)

As of 08/15/2025 07:56 PM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Cara Therapeutics NASDAQ:CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

MacroGenics NASDAQ:MGNX

$1.58 -0.04 (-2.47%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.58 -0.01 (-0.32%)

As of 08/15/2025 07:40 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Zura Bio NASDAQ:ZURA

$1.66 -0.06 (-3.49%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.72 +0.06 (+3.86%)

As of 08/15/2025 07:53 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time